Advances of combined immunotherapy in tumor
10.11665/j.issn.1000-5048.20180401
- VernacularTitle:肿瘤联合免疫治疗研究进展
- Author:
Rui ZHANG
1
;
Tao JIANG
;
Tianzhu ZENG
;
Wenbing YAO
;
Xiangdong GAO
;
Hong TIAN
Author Information
1. 中国药科大学江苏省生物药物成药性研究重点实验室，生命科学与技术学院
- Publication Type:Journal Article
- Keywords:
immunotherapy;
immune checkpoints;
combined treatment;
synergy
- From:
Journal of China Pharmaceutical University
2018;49(4):383-391
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoints are inhibitory signaling pathways in the immune system that maintain balance with co-stimulatory molecules, maintain tolerance to their own tissues, and avoid autoimmune responses. The development of tumors is accompanied by the upregulation of co-suppressor molecules and related ligands, causing the decline or exhaustion of T cell functions, which makes tumor cells excape immune surveillance. The development of monoclonal antibodies against inhibitory receptors and ligands to regulate T cell activity and improve antitumor immune responses have achieved promising clininal results. Combined treatment of immunomodulatory signaling pathways also showed a certain of synergy. This article summarizes the evaluation of combined tumor immunotherapy strategies and synergies, and outlooks the feasibility of combined immunotherapy and the selection of immunization strategies.
